专家委员会:使用复星及BioNTech疫苗益处多於风险 会将建议交予食卫局考虑
2019冠状病毒病疫苗顾问专家委员会召集人刘泽星於记者会上指,复星及德国药厂BioNTech(BNTX.US)的mRNA疫苗将於2月尾供港,委员会参考多项因素後认为在现时香港的疫情下,建议认可使用复星及BioNTech的疫苗的益处多於其风险,会将建议交予食卫局考虑,亦会将专业建议向公众公开,并将有关文件上载在食卫局网页供公众参考。
他指出专家委员会重视接种疫苗後出现不良反应及监测,卫生署已成立新的委员会,专家将会就每宗与疫苗相关的不良反应及临床评估等即时进行审核,而委员会成员由大学医学院及医管局专科医生担任。
委员会强调会要求复星更新临床数据、品质证明文件等,如顾问认为接种疫苗会令公众风险大於利益,会建议食卫局作出适切跟进行动,包括是建议取消有关认可。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.